A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Kastritis Efstathios; Leleu Xavier; Arnulf Bertrand; Zamagni Elena; Cibeira Maria Teresa; Kwok Fiona; Mollee Peter; Hajek Roman; Moreau Philippe; Jaccard Arnaud; Schonland Stefan; Filshie Robin; Nicolas-Virelizier Emmanuelle; Augustson Bradley; Mateos Maria-Victoria; Wechalekar Ashutosh; Hachulla Eric; Milani Paolo; Dimopoulos Meletios A.; Fermand Jean-Paul; Foli Andrea; Gavriatopoulou Maria; Palumbo Antonio; Sonneveld Pieter; Johnsen Hans Erik; Merlini Giampaolo; Palladini Giovanni

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

【24h】

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

机译：美法仑和地塞米松（MDex）与硼替佐米，美法仑和地塞米松（BMDex）治疗未经治疗的AL淀粉样变性患者的III期随机试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共6页
作者
Kastritis Efstathios; Leleu Xavier; Arnulf Bertrand; Zamagni Elena; Cibeira Maria Teresa; Kwok Fiona; Mollee Peter; Hajek Roman; Moreau Philippe; Jaccard Arnaud; Schonland Stefan; Filshie Robin; Nicolas-Virelizier Emmanuelle; Augustson Bradley; Mateos Maria-Victoria; Wechalekar Ashutosh; Hachulla Eric; Milani Paolo; Dimopoulos Meletios A.; Fermand Jean-Paul; Foli Andrea; Gavriatopoulou Maria; Palumbo Antonio; Sonneveld Pieter; Johnsen Hans Erik; Merlini Giampaolo; Palladini Giovanni;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis [J] . Kastritis Efstathios, Leleu Xavier, Arnulf Bertrand, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：美法仑和地塞米松（MDex）与硼替佐米，美法仑和地塞米松（BMDex）治疗未经治疗的AL淀粉样变性患者的III期随机试验
2. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. [J] . Mateos MV, Oriol A, Martinez Lopez J, The lancet oncology . 2010,第10期

机译：对于未经治疗的多发性骨髓瘤老年患者，硼替佐米，美法仑和泼尼松与硼替佐米，沙利度胺和泼尼松作为诱导疗法，然后采用硼替佐米和沙利度胺与硼替佐米和泼尼松维持治疗：一项随机试验。
3. Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen [J] . S J Jacobus, S V Rajkumar, M Weiss, Blood cancer journal. . 2016,第7期

机译：硼替佐米-来那度胺-地塞米松（VRd）与硼替佐米-地塞米松（Vd）合并完成地塞米松诱导治疗的多发性骨髓瘤患者的III期随机试验
4. RISK-ADAPTED INTRAVENOUS MELPHALAN WITH ADJUVANT THALIDOMIDE AND DEXAMETHASONE FOR NEWLY DIAGNOSED UNTREATED PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS: INTERIM REPORT OF A PHASE II TRIAL [C] . RL Comenzo, P Zhou, L Reich, International Symposium on Amyloidosis . 2005

机译：风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松，用于新诊断的未经治疗的全身淀粉样蛋白症患者：II期试验的中期报告
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT) [O] . Brian G. M. Durie, Antje Hoering, Rachael Sexton, 2020

机译：先前未经治疗的多发性骨髓瘤患者（Pts）的硼替佐米来那度胺和地塞米松vs来那度胺和地塞米松与无意立即进行自体干细胞移植（ASCT）的患者的随机随访III期SWOG S0777的长期随访
7. Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen [O] . Jacobus, S.J., Rajkumar, S.V., Weiss, M., 2016

机译：硼替佐米 - 来那度胺 - 地塞米松（VRd）与硼替佐米 - 地塞米松（Vd）联合治疗多发性骨髓瘤患者的随机III期临床试验已完成基于地塞米松的诱导方案

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

著录项

相似文献

相关主题

期刊订阅